Table 4.
Correlation between CD34 expression with clinicopathological features in prostate cancer
| Patients and tumor characteristics | n(%) | CD34 | χ2 | P-value | |
|---|---|---|---|---|---|
| ≤26 | >26 | ||||
| PSA level (ng/ml) | |||||
| < 10 | 19 (25.3) | 14 (73.7) | 5 (26.3) | 7.465 | 0.024 |
| 10 ~ 20 | 29 (38.7) | 13 (44.8) | 16 (55.2) | ||
| > 20 | 27 (36.0) | 9 (33.3) | 18 (66.7) | ||
| Gleason score | |||||
| ≤ 6 | 14 (18.7) | 11 (78.6) | 3 (21.4) | 9.731 | 0.008 |
| 7 | 28 (37.3) | 15 (53.6) | 13 (46.4) | ||
| 8 ~ 10 | 33 (44.0) | 10 (48.0) | 23 (69.7) | ||
| T stage | |||||
| T1–2 | 33 (44.0) | 24 (72.7) | 9 (27.3) | 14.436 | 0.000 |
| T3–4 | 42 (56.0) | 12 (28.6) | 30 (71.4) | ||
| Lymph node metastasis | |||||
| N0 | 46 (61.3) | 27 (58.7) | 19 (41.3) | 5.452 | 0.020 |
| N1 | 29 (38.7) | 9 (31.0) | 20 (69.0) | ||
| Distant metastasis | |||||
| M0 | 43 (57.3) | 28 (65.1) | 15 (34.9) | 11.829 | 0.001 |
| M1 | 32 (42.7) | 8 (25) | 24 (75.0) | ||
| TNM stage | |||||
| Stage II | 26 (34.7) | 18 (69.2) | 8 (30.8) | 7.187 | 0.007 |
| Stage III ~ IV | 49 (65.3) | 18 (36.7) | 31 (63.3) | ||
PSA prostate specific antigen